Clinical TrialMay 18, 2026, 05:02 PM
Telix completes IPAX-2 glioblastoma study enrollment; no DLTs
AI Summary
Telix Pharmaceuticals announced the completion of patient enrollment for its IPAX-2 study of TLX101-Tx (¹³¹I-iodofalan) for newly diagnosed glioblastoma. The study observed no dose-limiting toxicities, even at the maximum administered dose of 10GBq, supporting continued development. TLX101-Tx is also being evaluated in the pivotal IPAX BrIGHT trial for recurrent glioblastoma, which is actively dosing patients in Australia and the Netherlands. The company's PET imaging candidate TLX101-Px is used to identify suitable patients and monitor tumor response.
Key Highlights
- IPAX-2 study of TLX101-Tx for newly diagnosed glioblastoma completed patient enrollment.
- No dose-limiting toxicities (DLTs) observed in IPAX-2, even at maximum 10GBq dose.
- Twelve patients enrolled across three dose-escalating cohorts in Australia, Austria, and Netherlands.
- TLX101-Tx is also in pivotal IPAX BrIGHT trial for recurrent glioblastoma, actively dosing patients.
- IPAX BrIGHT is the first radiopharmaceutical therapy to enter Phase 3 development for glioblastoma.
- TLX101-Tx has received Orphan Drug Designation in the U.S. and Europe for the treatment of glioma.
Price Impact
More from TLX